Pasar al contenido principal

Neurocognitive features in the treatment of behavioural addictions and related eating disorders

FJC2021-046494-I

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Desarrollar, Atraer y Retener Talento
Subprograma Subprograma Estatal de Formación
Convocatoria Juan de la Cierva Formación
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACIO INSTITUT D INVESTIGACIO BIOMEDICA DE BELLVITGE (IDIBELL)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Anandamide and 2-arachidonoylglycerol baseline plasma concentrations and their clinical correlate in gambling disorder

  • Baenas, Isabel
  • Solé Morata, Neus, 1988-
  • Granero, Roser
  • Fernández Aranda, Fernando
  • Pujadas Bastardes, Mitona
  • Mora-Maltas, Bernat
  • Lucas, Ignacio
  • Gómez-Peña, Mónica
  • Moragas, Laura
  • Pino-Gutiérrez, Amparo del
  • Tapia-Martínez, Javier
  • Torre Fornell, Rafael de la
  • Potenza, Marc N.
  • Jiménez Murcia, Susana
Introduction: Different components of the endocannabinoid (eCB) system such as their most well-known endogenous ligands, anandamide (AEA) and 2-arachidonoylglycerol (2-AG), have been implicated in brain reward pathways. While shared neurobiological substrates have been described among addiction-related disorders, information regarding the role of this system in behavioral addictions such as gambling disorder (GD) is scarce. Aims: Fasting plasma concentrations of AEA and 2-AG were analyzed in individuals with GD at baseline, compared with healthy control subjects (HC). Through structural equation modeling, we evaluated associations between endocannabinoids and GD severity, exploring the potentially mediating role of clinical and neuropsychological variables. Methods: The sample included 166 adult outpatients with GD (95.8% male, mean age 39 years old) and 41 HC. Peripheral blood samples were collected after overnight fasting to assess AEA and 2-AG concentrations (ng/ml). Clinical (i.e., general psychopathology, emotion regulation, impulsivity, personality) and neuropsychological variables were evaluated through a semi-structured clinical interview and psychometric assessments. Results: Plasma AEA concentrations were higher in patients with GD compared with HC (p = .002), without differences in 2-AG. AEA and 2-AG concentrations were related to GD severity, with novelty-seeking mediating relationships. Conclusions: This study points to differences in fasting plasma concentrations of endocannabinoids between individuals with GD and HC. In the clinical group, the pathway defined by the association between the concentrations of endocannabinoids and novelty-seeking predicted GD severity. Although exploratory, these results could contribute to the identification of potential endophenotypic features that help optimize personalized approaches to prevent and treat GD., This research was supported by grants from the Delegación del Gobierno para el Plan Nacional sobre Drogas (2021I031), Plan Nacional sobre Drogas Convocatoria de subvenciones para proyectos de investigación financiados con fondos europeos 2022 (EXP2022/008847), Ministerio de Ciencia e Innovación (PDI2021-124887OB-I00 supported by MCIN/ AEI /10.13039/ 501100011033 and FEDER “Una manera de hacer Europa”), Instituto de Salud Carlos III (ISCIII) (FIS PI20/00132) and cofounded by FEDER funds/European Regional Development Fund (ERDF), a way to build Europe. CIBEROBN is an initiative of ISCIII. Additional funding was received by AGAUR-Generalitat de Catalunya (2021 SGR 00824 and 2021 SGR 00253) and European Union’s Horizon 2020 research and innovation program under grant agreement no. 847879 (PRIME/H2020, Prevention and Remediation of Insulin Multimorbidity in Europe) and no. 101080219 (eprObes). This study has also been funded by Instituto de Salud Carlos III through the grant CM21/00172 (I.B.) (cofunded by European Social Fund. ESF investing in your future). R.G. is supported by the Catalan Institution for Research and Advanced Studies (ICREA-Academia, 2021-Programme). I.L. is supported by the Ministerio de Ciencia e Innovación (MCIN), Agencia Estatal de Investigación (AEI), and by the European Union “NextGenerationEU/Plan de Recuperación, Transformación y Resiliencia (PRTR)” (Juan de la Cierva-Formación program, FJC2021–046494-I). M.N.P. was supported by the Connecticut Council on Problem Gambling. The funders had no role in the study design, data collection and analysis, decision to publish, or the preparation of the manuscript.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Anandamide and 2-arachidonoylglycerol baseline plasma concentrations and their clinical correlate in gambling disorder

  • Baenas, Isabel
  • Solé Morata, Neus, 1988-
  • Granero, Roser
  • Fernández Aranda, Fernando
  • Pujadas Bastardes, Mitona
  • Mora-Maltas, Bernat
  • Lucas, Ignacio
  • Gómez-Peña, Mónica
  • Moragas, Laura
  • Pino-Gutiérrez, Amparo del
  • Tapia-Martínez, Javier
  • Torre Fornell, Rafael de la
  • Potenza, Marc N.
  • Jiménez Murcia, Susana
Introduction: Different components of the endocannabinoid (eCB) system such as their most well-known endogenous ligands, anandamide (AEA) and 2-arachidonoylglycerol (2-AG), have been implicated in brain reward pathways. While shared neurobiological substrates have been described among addiction-related disorders, information regarding the role of this system in behavioral addictions such as gambling disorder (GD) is scarce. Aims: Fasting plasma concentrations of AEA and 2-AG were analyzed in individuals with GD at baseline, compared with healthy control subjects (HC). Through structural equation modeling, we evaluated associations between endocannabinoids and GD severity, exploring the potentially mediating role of clinical and neuropsychological variables. Methods: The sample included 166 adult outpatients with GD (95.8% male, mean age 39 years old) and 41 HC. Peripheral blood samples were collected after overnight fasting to assess AEA and 2-AG concentrations (ng/ml). Clinical (i.e., general psychopathology, emotion regulation, impulsivity, personality) and neuropsychological variables were evaluated through a semi-structured clinical interview and psychometric assessments. Results: Plasma AEA concentrations were higher in patients with GD compared with HC (p = .002), without differences in 2-AG. AEA and 2-AG concentrations were related to GD severity, with novelty-seeking mediating relationships. Conclusions: This study points to differences in fasting plasma concentrations of endocannabinoids between individuals with GD and HC. In the clinical group, the pathway defined by the association between the concentrations of endocannabinoids and novelty-seeking predicted GD severity. Although exploratory, these results could contribute to the identification of potential endophenotypic features that help optimize personalized approaches to prevent and treat GD., This research was supported by grants from the Delegación del Gobierno para el Plan Nacional sobre Drogas (2021I031), Plan Nacional sobre Drogas Convocatoria de subvenciones para proyectos de investigación financiados con fondos europeos 2022 (EXP2022/008847), Ministerio de Ciencia e Innovación (PDI2021-124887OB-I00 supported by MCIN/ AEI /10.13039/ 501100011033 and FEDER “Una manera de hacer Europa”), Instituto de Salud Carlos III (ISCIII) (FIS PI20/00132) and cofounded by FEDER funds/European Regional Development Fund (ERDF), a way to build Europe. CIBEROBN is an initiative of ISCIII. Additional funding was received by AGAUR-Generalitat de Catalunya (2021 SGR 00824 and 2021 SGR 00253) and European Union’s Horizon 2020 research and innovation program under grant agreement no. 847879 (PRIME/H2020, Prevention and Remediation of Insulin Multimorbidity in Europe) and no. 101080219 (eprObes). This study has also been funded by Instituto de Salud Carlos III through the grant CM21/00172 (I.B.) (cofunded by European Social Fund. ESF investing in your future). R.G. is supported by the Catalan Institution for Research and Advanced Studies (ICREA-Academia, 2021-Programme). I.L. is supported by the Ministerio de Ciencia e Innovación (MCIN), Agencia Estatal de Investigación (AEI), and by the European Union “NextGenerationEU/Plan de Recuperación, Transformación y Resiliencia (PRTR)” (Juan de la Cierva-Formación program, FJC2021–046494-I). M.N.P. was supported by the Connecticut Council on Problem Gambling. The funders had no role in the study design, data collection and analysis, decision to publish, or the preparation of the manuscript.